---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-013557"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:40:39.432231+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Protalix Q2 net loss narrows to $5.3M; PRX-102 Phase III CSR complete

## Summary
- Total revenues $8.8M ($3.4M product sales +$5.4M license/R&D), up 38% YoY.
- Net loss $5.3M ($0.11/share) vs. $11.2M ($0.25/share) in Q2 2021.
- Cash and equivalents $28.6M at June 30, 2022.
- Phase III BALANCE trial CSR confirms positive topline results for PRX-102 in Fabry disease.
- Appointed Shmuel Ben Zvi, Ph.D. to Board as Audit Committee Chairman.

## SEC filing metadata
- accession: 0001558370-22-013557
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837022013557/0001558370-22-013557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837022013557/plx-20220815x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-013557
- JSON: https://secwatch.observer/filing/0001558370-22-013557.json
- Plain text: https://secwatch.observer/filing/0001558370-22-013557.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.